EVX-04 / Evaxion - LARVOL DELTA

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting (GlobeNewswire) - "EVX-04 induces targeted immune responses and prevents tumor growth in preclinical models EVX-04 is an off-the-shelf therapeutic cancer vaccine developed for acute myeloid leukemia....The new data confirms that all 16 ERV fragments included in EVX-04 elicit a specific immune response and that EVX-04 prevents tumor growth in preclinical tumor models."

Preclinical • Acute Myelogenous Leukemia